ISLMF (InSilico Medicine Cayman TopCo) 12-1 Month Momentum %: N/A% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo 12-1 Month Momentum %?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 12-1 Month Momentum % is N/A% as of Aug. 27, 2026. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 2,769 Software companies, InSilico Medicine Cayman TopCo ranks worse than 36114.08% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-27), InSilico Medicine Cayman TopCo's 12-1 Month Momentum % is N/A%.

The industry rank for InSilico Medicine Cayman TopCo's 12-1 Month Momentum % or its related term are showing as below:

ISLMF's 12-1 Month Momentum % is not ranked *
in the Software industry.
Industry Median: -23.71
* Ranked among companies with meaningful 12-1 Month Momentum % only.

InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

InSilico Medicine Cayman TopCo 12-1 Month Momentum % Related Terms

ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
InSilico Medicine Cayman TopCo (ISLMF) has a 12-1 Month Momentum % of N/A% as of Aug. 27, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 2769 companies in the Software industry.
Is InSilico Medicine Cayman TopCo's 12-1 Month Momentum % too high?
InSilico Medicine Cayman TopCo's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 2769 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's 12-1 Month Momentum % compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 2769 companies for 12-1 Month Momentum %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Software company?
A good 12-1 Month Momentum % depends on the Software industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current 12-1 Month Momentum % is N/A% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price